Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 7/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | STAMBP | O95630 | 1/20 | 0.33 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21711526 | 0.74 | TSHR (0.42) | NNMTSMN1; SMN2TSHR | |
| SCHEMBL4333249 | 0.68 | NNMT (0.44) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL31461682 | 0.61 | NNMT (0.47) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL25787974 | 0.61 | TSHR (0.54) | NNMTSMN1; SMN2HPGDSTSHR | |
| SCHEMBL29664524 | 0.61 | NPC1 (0.43) | NNMTSMN1; SMN2HPGDSTSHR | |
| SCHEMBL28106132 | 0.60 | NNMT (0.46) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL35211576 | 0.59 | NNMT (0.45) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL9995934 | 0.59 | NNMT (0.39) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL3407188 | 0.59 | NNMT (0.56) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL30255493 | 0.58 | NNMT (0.47) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279681-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-10829462-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200055830-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279681-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | NNMT 2689/4885SMN1; SMN2 1067/4885PSMD14 1893/4885 |
| US-20200055830-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | NNMT 2689/4885SMN1; SMN2 1067/4885PSMD14 1893/4885 |
| US-10829462-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | NNMT 2689/4885SMN1; SMN2 1067/4885PSMD14 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.